Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to $7.7 million.

  • Treace Medical Concepts' Cash & Equivalents fell 3653.18% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 3653.18%. This contributed to the annual value of $11.4 million for FY2024, which is 1257.13% down from last year.
  • As of Q3 2025, Treace Medical Concepts' Cash & Equivalents stood at $7.7 million, which was down 3653.18% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Treace Medical Concepts' Cash & Equivalents registered a high of $119.6 million during Q2 2021, and its lowest value of $7.3 million during Q3 2023.
  • Its 5-year average for Cash & Equivalents is $42.2 million, with a median of $16.2 million in 2021.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 106080.54% in 2021, then crashed by 9178.05% in 2023.
  • Treace Medical Concepts' Cash & Equivalents (Quarter) stood at $105.8 million in 2021, then plummeted by 81.6% to $19.5 million in 2022, then crashed by 33.33% to $13.0 million in 2023, then fell by 12.57% to $11.4 million in 2024, then tumbled by 32.28% to $7.7 million in 2025.
  • Its Cash & Equivalents was $7.7 million in Q3 2025, compared to $8.1 million in Q2 2025 and $13.4 million in Q1 2025.